Navigation Links
Veterinary scientists explore poultry virus as cancer killer

Virologists in the Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM) at Virginia Tech are looking at how a genetically modified variant of Avian Newcastle disease virus (NDV) can treat human prostate cancer.

Dr. Elankurmaran Subbiah, assistant professor in the Department of Biomedical Sciences and Pathobiology, was awarded a prestigious research grant by the Department of Defense. This “Congressionally Directed Medical Research Program?award will support the exploration and hypothesis development for an innovative approach to treating prostate cancer.

Subbiah and his co-investigator, Dr. Siba K. Samal, associate dean, University of Maryland campus, received a $113,250 grant for their ongoing work using a genetically modified version of NDV to treat prostate cancer in humans.

Prostate cancer is the second most common type of cancer in men, according to the American Cancer Society (ACS). The ACS estimates there will be almost 219,000 new cases of prostate cancer reported in the United States in 2007.

According to Subbiah, the use of poultry viruses as cancer therapy poses no threat to humans and several other oncolytic viruses are currently being explored to treat cancer. However, Subbiah’s work is the first to alter Newcastle disease virus through a reverse genetic system to target prostate cancer specifically.

Reverse genetics is the process of generating a recombinant virus from cloned complimentary DNA (cDNA) copy of a viral genome, explains Subbiah. Through the reverse genetics system, recombinant viruses can be designed to have specific properties that make them attractive as biotechnological tools, live vaccines, and cancer therapeutics. This is achieved through the introduction of the desired changes in the cDNA, which are then transferred faithfully to the recombinant virus.

In the current investigation, Subbiah and his associates are altering the fusion protein of NDV to replica te only in the presence of prostate specific antigen (PSA), which is found exclusively in cancerous prostate cells.

Normal, healthy cells have an interferon antiviral system that activates upon infection with NDV thereby preventing replication of the virus, explains Dr. Subbiah. Cancer cells, however, have defective interferon antiviral systems, he said. NDV utilizes the defects to replicate in the diseased cells. The replication of NDV leads to the death of the cancer cell by a process called apoptosis - also known as programmed cell death or cell suicide- in the cell.


Source:Virginia Tech

Related biology news :

1. Researcher at UGA College of Veterinary Medicine identifies new way of combating viral diseases
2. Wisconsin scientists grow critical nerve cells
3. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
4. UAB scientists discover the origin of a mysterious physical force
5. Fox Chase Cancer Center scientists identify immune-system mutation
6. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
7. U-M scientists find genes that control growth of common skin cancer
8. UCLA scientists transform HIV into cancer-seeking missile
9. RNA project to create language for scientists worldwide
10. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
11. To control germs, scientists deploy tiny agents provocateurs
Post Your Comments:

(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology: